Faruqi and Faruqui, LLP Logo
Share this page

Aerie Pharmaceuticals, Inc. (AERI)

(NASDAQ: AERI)

Summary

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aerie Pharmaceuticals, Inc. (AERI) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Aerie Pharmaceuticals, Inc. (“Aerie” or the “Company”) (NASDAQ: AERI).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose material adverse information about the future prospects for its once-daily eye drop medication Rhopressa, designed to lower intraocular pressure (“IOP”) in patients with glaucoma or ocular hypertension.

On April 23, 2015, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa.  According to the press release, “[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.”

Following this unexpected news, shares of Aerie’s stock fell $22.52 per share, or over 63%, to close on April 24, 2015 at $12.87 per share.

Take Action

If you invested in Aerie stock or options between August 6, 2014 and April 23, 2015 and would like to discuss your legal rights, please contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Aerie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 05/11/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.